Suppr超能文献

复配肠胃外抗生素的成本控制:与制备、配药及给药相关的人员和供应成本。

Cost containment of reconstituted parenteral antibiotics: personnel and supply costs associated with preparation, dispensing, and administration.

作者信息

Tanner D J

出版信息

Rev Infect Dis. 1984 Nov-Dec;6 Suppl 4:S924-37. doi: 10.1093/clinids/6.supplement_4.s924.

Abstract

Time-and-motion studies were conducted to determine the time and cost associated with the dispensing, preparation, and administration of reconstituted parenteral antibiotics via the piggyback iv admixture (PBS) or volume control iv set administration (VCS) methods in six hospitals of various sizes. Supply costs were calculated for each system. National projections of potential cost savings resulting from decreased number of administrations of reconstituted parenteral antibiotics were made. The antibiotic class of parenteral cephalosporins was chosen as an example of where cost containment might be achieved. The estimated potential for total cost containment for the average hospital per hospital bed resulting from decreased number of administrations of first- and second-generation cephalosporins ranged from $76.64 (25% reduction in doses administered) to $229.92 (75% reduction) for the PBS method and, similarly, $47.02 to $141.08 for the VCS method. The projected potential national cost savings resulting from decreased number of administrations of first- and second-generation cephalosporins based on predicted antibiotic usage for 1983 ranged from $62.2 million (25% reduction in doses administered and adjusting for no conversion to intramuscular or intravenous push administrations) to $276.7 million (75% reduction). Clinicians and health-care managers should consider the cost-containment advantages provided by the substitution of newer antibiotics that permit reduced frequency of administration.

摘要

开展了时间与动作研究,以确定在六家不同规模医院中,通过静脉滴注混合液(PBS)或容量控制静脉输液器给药(VCS)方法,调配、制备和使用复溶后的肠胃外抗生素所需的时间和成本。计算了每个系统的供应成本。对因减少复溶后肠胃外抗生素的使用次数而可能节省的成本进行了全国性预测。选择肠胃外头孢菌素类抗生素作为可能实现成本控制的一个例子。对于PBS方法,平均每家医院每张病床因减少第一代和第二代头孢菌素的使用次数而实现的总成本控制潜力估计为76.64美元(给药剂量减少25%)至229.92美元(给药剂量减少75%);同样,对于VCS方法,这一数值为47.02美元至141.08美元。根据1983年预测的抗生素使用情况,因减少第一代和第二代头孢菌素的使用次数而预计在全国范围内可能节省的成本为6220万美元(给药剂量减少25%,且不考虑转换为肌肉注射或静脉推注给药的情况进行调整)至2.767亿美元(给药剂量减少75%)。临床医生和医疗保健管理人员应考虑使用允许减少给药频率的新型抗生素所带来的成本控制优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验